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ABSTRACT: The Src homology 2 domain containing protein
tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase
associated with various kinds of leukemia and solid tumors.
Thus, there is substantial interest in developing SHP2
inhibitors as potential anticancer and antileukemia agents.
Using a structure-guided and fragment-based library approach,
we identiﬁed a novel hydroxyindole carboxylic acid-based SHP2 inhibitor 11a-1, with an IC50 value of 200 nM and greater than
5-fold selectivity against 20 mammalian PTPs. Structural and modeling studies reveal that the hydroxyindole carboxylic acid
anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with
residues in the β5−β6 loop contribute to 11a-1’s binding potency and selectivity. Evidence suggests that 11a-1 speciﬁcally
attenuates the SHP2-dependent signaling inside the cell. Moreover, 11a-1 blocks growth factor mediated Erk1/2 and Akt
activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.
■ INTRODUCTION
Proper levels of tyrosine phosphorylation, maintained by the
reversible and coordinated actions of protein tyrosine kinases
(PTKs) and protein tyrosine phosphatases (PTPs), are critical
for a wide range of cellular processes including growth,
diﬀerentiation, metabolism, migration, and survival.1,2 Aberrant
tyrosine phosphorylation, as a result of perturbed balance
between the activities of PTKs and PTPs, is linked to the
pathogenesis of numerous human diseases, including can-
cer.1,3,4 Consequently, signaling events driven by tyrosine
phosphorylation oﬀer a rich source of molecular targets for
therapeutic interventions.5,6 The success of such targeted
approaches has been well demonstrated by the more than
two dozen PTK inhibitors that are already approved for clinical
uses.7 However, the therapeutic potential of modulating the
PTPs is still underexplored despite the fact that several PTPs
have also been identiﬁed as high-value targets.3,4
Excessive tyrosine phosphorylation is a hallmark of cancer,
usually caused by abnormal expression and/or activation of
receptor PTKs, such as epidermal growth factor receptor, and
nonreceptor PTKs such as Src and Abl.5 By catalyzing the
dephosphorylation of phosphotyrosine residues, PTPs are
usually viewed as negative regulators of signal transduction
and therefore perceived as products of tumor suppressor genes.
Indeed, several PTPs, including PTEN, have been identiﬁed as
tumor suppressors.8,9 However, recent genetic analyses of
human tumors reveal that at least 22 PTPs are candidate
oncoproteins.4 To this end, the Src homology 2 (SH2) domain
containing protein tyrosine phosphatase-2 (SHP2), encoded by
the Ptpn11 gene, positively potentiates cellular signaling.10−12
Biochemical and genetic studies establish that SHP2 promotes
signaling downstream from almost all growth factor and
cytokine receptors and upstream of Ras and is required for
growth factor/cytokine-induced cell proliferation, migration,
and survival. In addition, considerable evidence indicates that
SHP2 is a bona ﬁde oncoprotein. Germline gain-of-function
SHP2 mutations cause 50% of Noonan syndrome, an
autosomal dominant developmental disorder with increased
risk of malignancy.13,14 Moreover, somatic activating mutations
in SHP2 are associated with juvenile myelomonocytic leukemia,
acute myeloid leukemia, myelodysplastic syndrome, acute
lymphoid leukemia, and several types of solid tumors including
lung adenocarcinoma, colon cancer, neuroblastoma, glioblasto-
ma, melanoma, hepatocellular carcinoma, and prostate
cancer.15−24 Furthermore, SHP2 has also been implicated as
a therapeutic target for triple-negative and HER2+ breast
cancer.25 Finally, given the obligatory requirement of SHP2 in
multiple growth factor-mediated pathways, thwarting SHP2
activity may also prove eﬀective for cancers caused by abnormal
activation of receptor PTKs, some of which respond poorly to
kinase inhibitor monotherapy.26 This strong validation of SHP2
as an oncology target has generated considerable interest in the
development of small molecule SHP2 inhibitors as potential
therapeutic agents for hematologic malignancies and solid
tumors.27−41
Unfortunately, PTPs, including SHP2, have proven to be an
extremely diﬃcult target for drug discovery, due primarily to
the highly conserved and positively charged nature of its PTP
active site. Indeed, the majority of reported SHP2 inhibitors
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lack either appropriate selectivity or membrane permeability,
limiting their utility in modulating the activity of the
intracellular SHP2 phosphatase. We describe here a structure-
guided and fragment-based focused library approach, which led
to the development of a novel SHP2 inhibitor from the
hydroxyindole carboxylic acid scaﬀold. This inhibitor has an
IC50 of 200 nM for SHP2 that is over 5-fold more selective for
SHP2 than any of the over 20 tested PTPs. In addition, this
inhibitor eﬃcaciously blocks growth factor stimulated Erk1/2
activation and proliferation in a number of cancer cell lines,
validating the concept that small molecule SHP2 inhibitors may
be developed that eﬀectively treat solid cancers and leukemias.
■ RESULTS AND DISCUSSION
Structure-Guided and Fragment-Based Library Ap-
proach for Acquisition of SHP2 Inhibitors. The goal for
this study was to combine structure-guided design and
fragment-based focused library approach to obtain potent and
selective SHP2 inhibitors for preclinical evaluation and
pharmacological validation of SHP2 as an oncology drug
target. However, targeting PTPs for therapeutic development
has historically been shrouded with two major challenges. First,
the similarities between their active sites (i.e., the pTyr-binding
pockets) make it nearly impossible to develop small molecules
capable of inhibiting just one of the 100 plus PTPs encoded by
the human genome without inhibiting other closely related
family members. Second, ﬁnding compounds with high aﬃnity
for the positively charged PTP active site while at the same time
possessing favorable cell permeability also seems an insur-
mountable mountain to climb. To enhance both inhibitor
potency and selectivity, we have advanced a novel paradigm to
acquire compounds that interact not only with the pTyr-
binding pocket but also nearby peripheral sites that are unique
to particular PTPs.42,43 Application of this strategy has enabled
the identiﬁcation of a number of potent and selective PTP
inhibitors.44 To address the bioavailability issue, we sought to
identify nonhydrolyzable pTyr mimetics that possess suﬃcient
polarity to bind the PTP active site yet still capable of
penetrating cell membranes. We discovered that bicyclic
salicylic acids could serve as novel nonphosphorus-containing
pTyr mimetics and PTP inhibitors carrying a bicyclic salicylic
acid scaﬀold have excellent cellular eﬃcacies.35,45−49
To target both the active site and adjacent secondary binding
cavities in SHP2, Click reaction was initially utilized to tether
an alkyne-containing hydroxyindole carboxylic acid with 53
azide-containing amines and hydrazines.35 This led to the
identiﬁcation of II-B08 (Scheme 1), which exhibits an IC50 of
5.5 μM for SHP2 and several-fold selectivity against a panel of
mammalian PTPs. However, the potency and selectivity
displayed by II-B08 are still modest and insuﬃcient for further
pharmacological investigation. Given its promising in vitro and
in vivo activities,35,50,51 we envisioned that II-B08 could serve as
an excellent starting point upon which more potent and
selective SHP2 inhibitors can be developed. To guide the
design of next-generation SHP2 inhibitors, we solved the X-ray
crystal structure of SHP2 in complex with II-B08.35 The co-
crystal structure reveals that in addition to the hydroxyindole
carboxylic acid-dependent interactions with the SHP2 active
site, the distal phenyl ring in the biphenyl moiety is sandwiched
between the side chains of R362 and K364 in the β5−β6 loop
(residues 362−365). Interestingly, the β5−β6 loop is variable
among the PTPs, and interactions between the terminal
Scheme 1. Design and Synthesis of Hydroxyindole Carboxylic Acid Based Libraries 11a−da
aConditions: (a) FmocOSu, THF, reﬂux, 20 h, 81.4%; (b) Pd(PPh3)2Cl2, CuI, Na2CO3, DMF, 44%; (c) I2, NaHCO3, CH2Cl2 or AcCN, rt, 86%; (d)
50% diethylamine in DCM, 3 h, 85%; (e) 5% LiOH/THF = 1:2, 80 °C, 2 h, 97.2%; (f) corresponding acyl chloride, Et3N, DMF, 0 °C, 80−90%; (g)
5% LiOH/THF = 1:2, rt, 2 h, 80−90%; (h) 192 amines, HOBT, HBTU, DIPEA, DMF, rt, overnigh,. 60−80%.
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biphenyl group and residues R362 and K364 likely contribute
to the observed potency and selectivity of II-B08.35 Little
interaction was observed between SHP2 and the 2-phenyl
group (the α-ring) directly attached to the hydroxyindole
carboxylic acid core. In addition, there was no signiﬁcant
contact between the triazol linker and SHP2. Molecular
modeling indicated that appropriately functionalized substitu-
ents placed at the meta-position of the α-ring could increase
inhibitor binding to SHP2 active site and the β5−β6 loop. To
this end, we devised a fragment-based focused library strategy
(Scheme 1) to transform the hydroxyindole carboxylic acid
scaﬀold into highly potent and selective SHP2 inhibitors. The
libraries contain (1) the hydroxyindole carboxylic acid core to
target SHP2 active site, (2) proper linkers to connect the
hydroxyindole carboxylic acid to (3) a structurally diverse
collection of amines, intended to capture additional interactions
with the adjacent β5−β6 loop. In the interest of keeping the
libraries to a manageable size, we chose 192 commercially
available amines that diﬀer in size, charge, hydrophobicity,
polarity, solubility, and drug-like properties, which should
provide a reasonable (albeit limited) structural diversity to
increase the number and strength of noncovalent interactions
between SHP2 and the inhibitor. To ensure that library
components can optimally bridge both the active site cavity and
the adjacent peripheral site in SHP2, a spacer of 0−3 methylene
units was introduced between the two carbonyls in the amino-
oxo acylamido phenyl linker (Scheme 1).
To construct the bidentate libraries (Scheme 1), amine 1 was
protected with FmocOSu to produce alkyne 2. Alkyne 2 was
coupled with iodide 3 by Sonogashira reaction to aﬀord
compound 4 with 44% yield.47 Electrophilic cyclization of 4 by
I2 furnished compound 5 in 86% yield. Deprotection of 5 under
50% diethylamine in DCM aﬀorded amine 6. Compound 7 was
obtained by hydrolysis of 6 in 5% LiOH under 80 °C for 2 h.
Compound 7 upon treatment with acetyl chlorides 8a−d
yielded compounds 9a−d, which were hydrolyzed in 5% LiOH
at room temperature for 2 h to produce compounds 10a−d. To
assemble libraries 11a−d, 192 structurally diverse amines were
introduced, in equal quantities, into individual wells of two 96-
well plates in the presence of HOBT, HBTU, and DIPEA in
DMF to condense with the carboxylic acid in compounds 10a−
d overnight. The quality of the reactions in the wells was
Table 1. IC50 Values (μM) of Top Hits from Library 11a for SHP2
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randomly monitored by LC-MS, indicating that 60−80% of
compounds 10a−d was converted to the desired products.
Libraries 11a−d were screened at ∼5 μM for SHP2
inhibitors without further puriﬁcation. The ability of the library
components to inhibit the SHP2-catalyzed hydrolysis of p-
nitrophenyl phosphate (pNPP) was evaluated at pH 7 and 25
°C. It became immediately evident from the initial screening
results that the linker length is of critical importance. In fact, all
of the top hits were from library 11a, which had the shortest
oxalic linker. The top 20 hits from library 11a were
resynthesized, puriﬁed by HPLC, and their IC50 values
determined. As can be seen from Table 1, the IC50 values
matched well with the percent inhibition data measured at ∼5
μM compound concentration. The best hit compound 11a-1
identiﬁed from the screen also exhibited the lowest IC50 value
of 0.20 ± 0.02 μM against SHP2. Similar to 11a-1, other
compounds bearing a biaryl substituent (e.g., 11a-2 and 11a-5)
also strongly inhibited SHP2. Interestingly, compounds with
the benzyloxyphenyl amino scaﬀold (e.g., 11a-3 and 11a-6)
also inhibited SHP2 at submicromolar concentration. To
further establish biaryl substituents as privileged structures for
SHP2 binding, we synthesized six additional biaryl substituted
derivatives of 11a-1 (Table 2). As expected, the IC50 values of
compounds 11a-21 to 11a-26 are comparable to that of 11a-1.
To conﬁrm the eﬀectiveness of oxalic linker, we resynthesized
and characterized 11 top hits from library 11c (with a succinic
linker). In agreement with the results from screening, the hits
selected from library 11c were less potent than their library 11a
counterparts (Table 1 and Table 3). For example, 11c-1, the
top hit from library 11c, had an IC50 of 2.3 μM, more than 10
times higher than that of 11a-1 (IC50 = 0.20 μM). Collectively,
the structure and activity data indicate that the aromatic oxalic
linker and biaryl substituents are preferred for enhanced
inhibitor binding toward SHP2. Selectivity proﬁling revealed
that 11a-1 exhibits over 5-fold selectivity for SHP2 over a large
panel of 20 mammalian PTPs, including receptor-like PTPs,
PTPμ, PTPε, PTPα, PTPσ, and PTPγ, cytosolic PTPs, PTP1B,
Lyp, SHP1, PTPH1, HePTP, STEP, and PEZ, the dual
speciﬁcity phosphatase VHR, VHZ, MKP5, CDC14A,
UBLCP1, and Laforin, and the low-molecular-weight PTP
and SSu72 (Table 4). Of particular note, compound 11a-1
displayed a 7- and 11-fold preference for SHP2 over its closely
related homologue SHP1 and PTP1B. To the best of our
knowledge, 11a-1 is the most potent SHP2 inhibitor reported
to date.
Structural Basis of SHP2 Inhibition by Compound
11a-1 and 11c-9. To elucidate the structural basis of SHP2
inhibition by 11a-1, we sought to determine the crystal
structure of the SHP2 PTP domain (residues 240−528) in
complex with 11a-1. Unfortunately, no diﬀraction quality
crystals were obtained for the complex. Instead, we were able to
cocrystallize SHP2 with 11c-9 and solved the crystal structure
of SHP2 in complex with 11c-9 (Table 3, IC50 = 14 μM). The
SHP2·11c-9 complex crystallized in space group P1 with one
molecule in the asymmetric unit. The crystals of the SHP2·11c-
9 complex diﬀracted to 2.1 Å resolution, and the structure was
solved by molecular replacement, using the apo-form of SHP2
catalytic domain (PDB: 3B7O)52 as the search model. The
three-dimensional structure of SHP2·11c-9 was reﬁned to a
Table 2. IC50 Values (μM) of 11a-21 to 11a-26 for SHP2
Table 3. IC50 Values (μM) of Top Hits from Library 11c for
SHP2
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crystallographic R-factor of 18.7% (Rfree = 22.1%), and the
statistics for data collection and reﬁnement are shown in Table
5. The atomic model includes SHP2 residues 246−314 and
323−526, and all atoms of the compound 11c-9 (Figure 1).
The overall structure of SHP2·11c-9 is similar to the ligand
free SHP2 structure used for molecular replacement, with the
root-mean-square-deviation (rmsd) for all α-carbon positions
between the two being 0.53 Å. A major diﬀerence between the
two structures are electron density in the SHP2 active site
corresponding to 11c-9, which was conﬁrmed by the |Fo| − |Fc|
diﬀerence map contoured at 2.5σ (Figure 1A). As expected, the
hydroxyindole carboxylic acid moiety in 11c-9 occupies the
SHP2 active-site pocket and forms extensive interactions with
residues in the P-loop (residues 458−465), the pY recognition
loop (residues 277−284), and the Q loop (residues 501−507)
(Figure 1B). Speciﬁcally, the phenolic oxygen O1 within the
hydroxyindole carboxylic acid core makes two hydrogen bonds
with the side chain of R465 in the P-loop; the carboxylate O2 is
hydrogen bonded to the main chain amide of R465, and O3
contributes one H-bond with the main chain amide of A461
and one polar interaction with the side chain of S460. The
indole ring interacts favorably with the side chains of S460,
A461, and R465 in the P-loop as well as the side chains of
Q506, T507, and Q510 in the Q-loop, and the iodine atom at
the 3-position of the indole ring has van der Waals contacts
with the side chain of Y279. Interestingly, the distal
benzodioxol ring in 11c-9 is also involved in polar and
nonpolar interactions with the side chain of K364 in the β5−β6
loop (residues 362−365). Finally, the succinic linker makes van
der Waals contacts with both the side chain of R362 in the
β5−β6 loop and the side chain of H426 in the WPD loop
(residues 421−431), whereas the carbonyl oxygen O4 in the
linker forms a polar interaction with the side chain of R362.
Guided by our previous SHP2·II-B08 structure35 and the
current SHP2·11c-9 structure, we sought to understand the
molecular basis of compound 11a-1 mediated SHP2 inhibition
by carrying out docking studies within the area that covers both
II-B08 and 11c-9 around the SHP2 active site. As shown in
Figure 2A, the overall SHP2 binding mode of 11a-1 (green
Table 4. Selectivity of 11a-1 against a Panel of PTPs
PTP IC50 (μM) PTP IC50 (μM)
SHP2 0.20 ± 0.02 VHR 3.2 ± 0.1
LYP 1.05 ± 0.02 PTPμ 3.3 ± 0.2
HePTP 1.03 ± 0.08 STEP 4.0 ± 0.2
PTPH1 1.07 ± 0.07 PEZ 5.3 ± 0.2
SHP1 1.44 ± 0.04 PTPσ 8.6 ± 0.4
Ssu72 1.3 ± 0.2 UBLCP1 9.7 ± 0.5
PTP1B 2.29 ± 0.03 laforin 12.2 ± 2
LMWPTP 2.34 ± 0.02 CDC14A 16 ± 4
VHZ 2.3 ± 0.2 PTPε >20
PTPγ 2.4 ± 0.4 PTPα >100
MKP5 2.9 ± 0.1
Table 5. Data Collection and Reﬁnement Statistics
SHP2·11c-9
crystal parameters
space group P1
cell dimensions
a (Å) 40.0
b (Å) 40.9
c (Å) 48.9
α (deg) 94.6
β (deg) 109.2
γ (deg) 110.0
data collection
resolution range (Å) 50.0−2.1
no. of unique reﬂections 12808
completeness (%) 82.3
redundancy 2.5
Rmerge
a 0.071
reﬁnement
resolution range (Å) 50.0−2.5
no. of reﬂections used (F ≥ 2.0δ (F)) 8843
completeness (%) 94.9
no. of protein atoms 2219
no. of inhibitors 1
Rwork
b/Rfree
c 18.7/22.1
rms deviations from ideal geometry
bond length (Å) 0.0079
bond angle (deg) 1.33
aRmerge = ∑h ∑i|I(h)i − ⟨I(h)⟩|/∑h∑iI(h)i. bRwork = ∑h|F(h)calcd −
F(h)obsd|/∑hF(h)obsd, where F(h)calcd and F(h)obsd were the reﬁned
calculated and observed structure factors, respectively. cRfree was
calculated for a randomly selected 3.9% of the reﬂections that were
omitted from reﬁnement.
Figure 1. Crystal structure of SHP2 in complex with compound 11c-9.
(A) Overall structure of SHP2 in complex with 11c-9. The P-loop is
shown in pink, the WPD-loop in blue, the Q-loop in green, the pY-
loop in orange, and the β5−β6 loop in cyan. Compound 11c-9 is
shown in stick model with unbiased Fo − Fc map contoured at 2.5σ
calculated before the ligand and water molecules were added to the
model. (B) Detailed interactions between compound 11c-9 and SHP2.
Polar interactions or H-bonds are shown by red dashed lines.
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carbon) is similar to those of II-B08 (cyan carbon) and 11c-9
(purple carbon). In all three cases, the hydroxyindole carboxylic
acid motif penetrates into the active site, and the distal
heterocycle tail interacts with a groove formed by residues in
the β5−β6 loop. However, unlike II-B08 or 11c-9, which extend
their heterocycle tail to the groove via their ﬂexible linkers
primarily along the Q-loop and WPD-loop, compound 11a-1
spreads its tail through the rigid oxalic linker along the pY
recognition loop. Consequently, the hydroxyindole carboxylic
acid in 11a-1 binds more deeply into the active site along the
pY recognition cleft, occupies most of the active site pocket
(Figure 2B), and the adjacent α-phenyl ring forms strong π−π
stacking interaction with Y279 in the pY recognition loop
(Figure 2C), which is not observed in SHP2·II-B08 and SHP2·
11c-9 structures. In addition, the oxalamide linker properly
places the phenylthiophene tail to be well sandwiched by R362
and K364 in the β5−β6 loop (Figure 2D). In more detail
(Figure 2E), the hydroxyindole carboxylic acid forms four H-
bonds with the backbone amides of S460, I463, G464, and
R465 in the P-loop, which anchors the indole core in the active
Figure 2. SHP2 binding mode by 11a-1 revealed by molecular docking. (A) The overall binding mode of 11a-1 (green carbon stick) with SHP2
(represented by transparent surface). The binding modes of II-B08 (cyan carbon stick) and 11c-9 (purple carbon stick) from the complex structures
are shown for comparison. (B) The hydroxyindole carboxylic acid motif (spheres) penetrating deeply into the SHP2 active site along the pY
recognition cleft. (C) The α-phenyl ring (spheres) forms strong π−π stack interaction with Y279 (gray carbon stick with dotted surface). (D) The
rigid oxalamide linker orients the phenylthiophene (spheres) to be well sandwiched by R362 and K364 (gray carbon stick). (E) The interaction
details between 11a-1 (green carbon stick) with SHP2. Residues within 5 Å distance to 11a-1 are shown in stick. P-loop is highlighted in red, and the
other three loops are in blue.
Figure 3. SHP2 inhibitor 11a-1 reduced lung cancer cell proliferation and speciﬁcally blocked SHP2-dependent signaling. (A) 11a-1 dose
dependently inhibited H1975 proliferation with an IC50 of 0.17 ± 0.02 μM. (B) 11a-1 decreased EGF induced Erk1/2 phosphorylation and
increased EGF induced paxillin (Y118) phosphorylation in a dose-dependent manner. (C) The structurally related negative control 10a failed to
block SHP2-dependent signaling at 2 μM. (D) the ability of 11a-1 to inhibit Erk1/2 activation was blunted in SHP2 knocked down cells, and (E)
11a-1 had no eﬀect on PMA-stimulated Erk1/2 phosphorylation.
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site to be in van der Waals contacts with several P-loop
residues, the 1-methyl group makes hydrophobic interactions
with A461, Y279, and I282 and the α-phenyl ring π−π stacks
with Y279, and one of the carbonyls within the oxalamide linker
forms H-bond with the side chain of K364, which thus orients
the phenylthiophene tail between R362 and K364 in the β5−β6
loop. Collectively, the increased and more favorable inter-
actions between 11a-1 and SHP2 likely contribute to 11a-1’s
enhanced inhibition potency and selectivity toward SHP2. To
corroborate the proposed 11a-1 binding mode, we carried out
site-directed mutagenesis to convert the β5−β6 loop residues
R362 and K364 to Ala and Ser, respectively. The R362A and
K364S mutants displayed similar kcat and Km to those of the
wild-type SHP2. However, the IC50 values of 11a-1 for R363A
and K364S were 2.2- and 1.5-fold higher than that of wild-type
SHP2. These results are in agreement with the binding mode
observed from the docking analysis, supporting the conclusion
that interactions between 11a-1 and R362/K364 contribute to
the enhanced potency of 11a-1 for SHP2.
SHP2 Inhibitor 11a-1 Displays Activity in Several
Cancerous Cell Lines. Our goal is to develop potent and
speciﬁc SHP2 inhibitors as novel anticancer and antileukemia
agents. Previous studies have established that SHP2 promotes
growth factor-mediated Ras-Erk1/2 activation and cell
proliferation.10−12 Given 11a-1’s excellent potency and
selectivity toward SHP2, we evaluated its ability to inhibit
SHP2-dependent signaling and proliferation in a number of
cancer cell lines. We previously demonstrated that SHP2 is
required for growth of H1975,51 a nonsmall cell lung cancer
(NSCLC) patient-derived cell line with secondary gatekeeper
mutations in EGF receptor and showing resistance to EGF
receptor inhibitors geﬁtinib and erlotinib.53,54 To determine the
eﬀect of SHP2 inhibition by 11a-1, H1975 cells were treated
with various concentrations of 11a-1 and the cell number was
measured by the MTT assay. As shown in Figure 3A, 11a-1
inhibited H1975 cell proliferation in a dose-dependent manner
with an IC50 of 0.17 ± 0.02 μM.
Because SHP2 phosphatase activity is required for the full
activation of the Ras-Erk1/2 pathway,10,55 we assessed the
cellular eﬀect of 11a-1 on EGF-induced Erk1/2 activation in
H1975 cells. As expected, 11a-1 eﬀectively reduced the EGF-
induced Erk1/2 phosphorylation in a dose-dependent manner
(Figure 3B). To provide direct evidence that 11a-1 can block
the phosphatase activity of SHP2 inside the cell, we measured
the phosphorylation level of Paxillin (pY118), a physiological
substrate of SHP2 whose dephosphorylation by SHP2
enhances EGF-stimulated Erk1/2 activation.56 As shown in
Figure 3B, treatment of H1975 cells with 11a-1 dose
dependently increased Paxillin phosphorylation on Y118,
which is consistent with the decreased EGF-induced Erk1/2
activation in the presence of 11a-1.
To ensure that the cellular activity of 11a-1 is manifested
through SHP2 inhibition and not due to nonspeciﬁc eﬀects, a
structurally related but signiﬁcantly less inhibitory compound
10a (IC50 of 14.4 μM for SHP2, Table 1) was also evaluated. As
expected, at 2 μM compound 10a exerted no eﬀect on Paxillin
and Erk1/2 phosphorylation while at the same concentration
compound 11a-1 reduced Erk1/2 phosphorylation by 40% and
augmented Paxillin phosphorylation by 30% (Figure 3C).
Moreover, the ability of 11a-1 to attenuate EGF-mediated
Erk1/2 activation was blunted when the level of SHP2 was
knocked down with siRNA. As shown in Figure 3D, at 2 μM
concentration 11a-1 reduced Erk1/2 phosphorylation by 2.2-
fold in cells treated with scrambled siRNA but only 1.5-fold in
cells treated with SHP2 siRNA. To provide further evidence
that the observed cellular eﬀect of 11a-1 is SHP2 dependent,
we examined the eﬀect of 11a-1 on PMA (phorbol 12-myristate
13-acetate)-induced Erk1/2 activation, which is SHP2
independent57 and instead depends on the activation of protein
kinase C and Raf58 in a Ras-independent manner.59 Thus,
SHP2 inhibitors would not be expected to aﬀect PMA-induced
Erk1/2 phosphorylation. Indeed, compound 11a-1 had no
eﬀect on PMA-induced Erk1/2 phosphorylation (Figure 3E).
Taken together, the results indicate that 11a-1 speciﬁcally
inhibits SHP2-mediated cellular signaling events.
The promising activity of 11a-1 in inhibiting H1975 lung
cancer cell proliferation spurred an investigation into its
eﬀectiveness on inhibiting the growth of the ErbB2 positive
SKBR3 breast cancer cell line. These cells through upregulation
of ErbB2 strongly activate Ras, which then promotes either Akt
signaling when grown on plastic or Erk1/2 signaling when
grown in Matrigel.60 Given the multitude of studies that show
that cancer cells grow in Matrigel as a mass that much more
closely models the formation and signaling properties of real
human tumors,61 the eﬀectiveness of 11a-1 in blocking the
growth of these cells in Matrigel was determined. Consistently,
SKBR3 cells formed tumor like growths in Matrigel treated
with vehicle but their growth within 24 h was potently inhibited
by 3 μM of 11a-1 (Figure 4A). Further, while both control and
Figure 4. Compound 11a-1 inhibits Erk1/2 and Akt activity and
ErbB2+ breast cancer cell growth in a 3D Matrigel environment. (A)
SKBR3 cells were seeded into Matrigel, and their growth was then
monitored over 4 days in the presence of vehicle or the indicated
concentrations of 11a-1. (B) Cells after 4 days of growth in Matrigel
were recovered and the levels of the total and phospho forms of Erk1/
2 and Akt were measured by immunoblot.
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11a-1 treated cells showed equivalent levels of total Erk1/2 and
Akt over 4 days, their levels of phosphorylation were
concordantly inhibited by increasing concentrations 11a-1
from 1 to 10 μM (Figure 4B). Taken together, 11a-1 potently
inhibits the growth of the ErbB2 positive SKBR3 cell line, most
likely through its ability to block SHP2-dependent Erk1/2 and
Akt activation.
Gain-of-function mutations in KIT receptor (KITD814V) in
humans are associated with gastrointestinal stromal tumors,
systemic mastocytosis, and acute myelogenous leukemia.62,63
We have previously shown that our ﬁrst-generation SHP2
inhibitor II-B08 suppresses the growth of oncogenic
KITD814V-induced ligand-independent growth.50 To further
determine the eﬃcacy of the new SHP2 inhibitor 11a-1, we
compared the growth of oncogenic KITD814V-bearing 32D
myeloid cells in the presence of II-B08 and 11a-1. As seen in
Figure 5A, we did not see any signiﬁcant suppression in the
growth of wild-type KIT-bearing cells in the presence of II-B08
or 11a-1 at the tested concentrations. This was to be expected
because SHP2 exists in an autoinhibited conformation in the
absence of ligand stimulated KIT activation.50 In contrast,
treatment with II-B08 at 5 μM showed signiﬁcant suppression
in ligand-independent growth of KITD814V-bearing cells but
not at 1 μM concentration. Furthermore, treatment with 11a-1
showed signiﬁcant inhibition of ligand-independent growth of
KITD814V-bearing cells at both 1 and 5 μM concentrations.
To further determine the eﬀect of II-B08 and 11a-1 on primary
bone marrow cells bearing oncogenic KITD814V, we
transduced primary low-density bone marrow cells from
C57BL/6 mice with KITD814V and sorted cells were subjected
to proliferation assay in the presence or absence of SHP2
inhibitors II-B08 and 11a-1. Similar to 32D myeloid cells,
primary bone marrow cells bearing KITD814V showed
signiﬁcant reduced growth in the presence of 11a-1 compared
to II-B08 at both 1 and 5 μM concentrations (Figure 5B).
These results suggest that 11a-1 is more potent in inhibiting
oncogenic KITD814V-induced constitutive growth compared
to II-B08.
Previous studies have shown that SHP2 controls the cell
growth and survival through regulation of the activation of Akt
and Erk1/2 signaling. We also found that SHP2 inhibitor II-
B08 suppresses the activation of Akt in oncogenic KITD814V-
bearing cells. To determine whether SHP2 inhibitor 11a-1 also
suppress the ligand-independent activation of Akt and Erk1/2
signaling, we starved the 32D myeloid cells bearing wild-type
KIT or KITD814V and treated them with 11a-1. Consistent
with our previous results, cells bearing wild-type KIT did not
show any constitutive activation of Akt or Erk1/2 in the
presence or absence of 11a-1 (data not shown). Likewise,
constitutive phosphorylation of Akt and Erk1/2 was observed
in oncogenic KITD814V-bearing cells (Figure 5C, lane 1).
There was dose-dependent inhibition of phosphorylation of Akt
and Erk1/2 in the presence of 11a-1 (Figure 5C, lanes 2−4).
These results suggest that 11a-1 inhibits the activation of Akt
and Erk1/2 signaling, leading to reduced growth of oncogenic
KITD814V-bearing cells. Collectively, the results described
above indicate that 11a-1 is highly eﬃcacious in blocking SHP2
activity and cell proliferation in H1975 lung cancer cells, ErbB2
positive SKBR3 breast cancer cells, and oncogenic KITD814V-
bearing 32D myeloid cells and primary low-density bone
marrow cells.
■ CONCLUSION
In summary, we report a novel hydroxyindole carboxylic acid-
based inhibitor for SHP2, an oncogenic phosphatase required
for multiple growth factor receptor signaling and implicated in a
broad-spectrum of cancer and leukemia. We took a structure-
guided approach that targets the SHP2 active site with
hydroxyindole carboxylic acid and relies on a fragment-based
library strategy to introduce additional functionalities intended
to interact with peripheral sites proximal to the catalytic pocket
to increase binding aﬃnity and selectivity for SHP2. This led to
the transformation of a modest 5.5 μM hit II-B08 into a 200
nM SHP2 inhibitor 11a-1 with greater than 5-fold selectivity
against a large panel of mammalian PTPs. Structural analysis
and molecular modeling reveal that the hydroxyindole
carboxylic acid anchors the inhibitor to the SHP2 active site
while interactions of the oxalamide linker and phenylthiophene
tail with residues in the β5−β6 loop contribute signiﬁcantly to
11a-1’s binding potency and selectivity toward SHP2. We
provide evidence that 11a-1 displays highly eﬃcacious cellular
activity and can speciﬁcally block the SHP2-dependent
signaling inside the cell. Moreover, 11a-1 attenuates growth
factor mediated Erk1/2 and Akt activation and exhibits
excellent antiproliferative activity in nonsmall cell lung cancer
cell line H1975, ErbB2 positive breast cancer cell line SKBR3,
and oncogenic KITD814V expressing 32D myeloid cells and
primary low-density bone marrow cells. Thus, compound 11a-1
Figure 5. Eﬀects of compound 11a-1 on 32D cells. (A) 32D myeloid
cells bearing wild-type (WT) KIT or KITD814V were starved of
serum and growth factors for 6 h and subjected to proliferation assay
in the presence or absence of indicated concentration of II-B08 or 11a-
1. Assay was performed in the presence of IL-3 (10 ng/mL) for cells
bearing WT KIT and in the absence of growth factors for cells bearing
oncogenic KITD814V. Bars denote the mean thymidine incorporation
(CPM ± SEM) consolidated from four independent experiments
performed in triplicate. *p < 0.05. (B) WT hematopoietic stem and
progenitor cells bearing KITD814V were starved of serum and growth
factors for 6 h and subjected to proliferation assay in the presence or
absence of indicated concentration of II-B08 or 11a-1. Bars denote the
mean thymidine incorporation (CPM ± SD) performed in triplicate
from one experiment. *p < 0.05. (C) 32D myeloid cells bearing
KITD814V were starved of serum and growth factors for 6 h and
incubated with the indicated concentration of 11a-1 for 2 h. After
treatment, cells were lysed and equal amount of protein lysates were
subjected to Western blot analysis using indicated antibodies. Similar
results were observed in two independent experiments.
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not only serves as a promising candidate for the development of
novel agents for a wide range of neoplastic disorders but also a
useful tool to interrogate the function of SHP2 in normal
physiology and to elucidate the events underlying SHP2-evoked
transformation. Obtaining this knowledge is vital for under-
standing SHP2-mediated oncogenic mechanisms and for the
development of novel anticancer and antileukemia therapies
targeted to SHP2.
■ EXPERIMENTAL SECTION
Materials. para-Nitrophenyl phosphate (pNPP) was purchased
from Fisher Scientiﬁc. For organic synthesis, reagents were used as
purchased (Aldrich, Acros, Alfa Aesar, TCI) except where noted.
Rabbit antiphospho-Akt, antitotal Akt, antiphospho-Erk1/2, antitotal
Erk1/2, and anti-phospho-Paxillin (Tyr118) antibodies were pur-
chased from Cell Signaling Technology (Beverly, MA). Anti-Paxilin
antibodies were from BD Transduction Laboratories. Recombinant
murine interleukin-3 (IL-3), murine stem cell factor (SCF), murine
thrombopoietin (TPO), and murine FLT3 ligand (FLT3-L) were
purchased from Peprotech (Rocky Hill, NJ). Iscove’s Modiﬁed
Dulbecco’s Medium (IMDM) was purchased from Invitrogen
(Carlsbad, CA). [3H] Thymidine was purchased from PerkinElmer
(Boston, MA).
General Procedures. 1H and 13C NMR spectra were obtained on
Bruker 500 spectrometers with TMS or residual solvent as standard.
All column chromatography was performed using Dynamic
Adsorbents 230−400 mesh silica gel (SiO2) with the indicated solvent
system unless otherwise noted. TLC analysis was performed using 254
nm glass-backed plates and visualized using UV light (254 nm), and
low-resolution mass spectra and purity data were obtained using an
Agilent Technologies 6130 Quadrupole LC/MS. The purity of the
compounds were assessed by analytical HPLC, with the solvent
gradient started at 0% methanol in water and ended at 100% methanol
after 8 min with 0.1% of TFA. The purity of all ﬁnal tested compounds
was determined to be >95% (UV, λ = 254 nm). High-resolution mass
spectrum data were collected on an Agilent 6520 Accurate-Mass Q-
TOF LC/MS. HPLC puriﬁcation was carried out on a Waters Delta
600 equipped with a Sunﬁre Prep C18 OBD column (30 mm × 150
mm, 5 μm) with methanol−water (both containing 0.1% TFA) as
mobile phase. The preparative HPLC gradient started at 50%
methanol in water and ended at 100% methanol after 40 min with
0.1% of TFA.
(9H-Fluoren-9-yl)methyl (3-Ethynylphenyl)carbamate (2). Mix-
tures of compound 1 (0.75 mL, 7.18 mmol) and Fmoc-OSu (2.664 g,
7.89 mmol) in 200 mL of THF were reﬂuxed overnight. The solution
was partitioned between EtOAc and water. The residue was puriﬁed by
ﬂash silica chromatography (Hex/EtOAc = 8:1) to aﬀord titled
compound as white solid (1.98 g, 81.4%); mp 137−138 °C. 1H NMR
(500 MHz, CDCl3): δ 7.83 (m, 2H), 7.61 (m, 2H), 7.54 (brs, 1H),
7.36 (m, 3H), 7.28 (m, 2H), 7.23 (m, 1H), 7.21 (m, 1H), 6.66 (brs,
1H), 4.57 (d, J = 6.6 Hz, 2H), 4.30 (t, J = 6.6 Hz, 1H), 3.08 (s, 1H).
13C NMR (125 MHz, DMSO): δ 153.8, 144.1, 141.2, 139.8, 129.6,
128.1, 127.5, 126.2, 125.5, 122.5, 121.5, 120.6, 119.3, 83.5, 80.9, 66.1,
47.0. HRMS (ESI): (M + H)+ calcd for C23H18NO2, 340.1332; found,
340.1341. LC-MS (ESI): 362.0 (M + Na)+. Purity: >95% (UV, λ = 254
nm).
Methyl 5-((3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-
phenyl)ethynyl)-4-(dimethylamino)-2-hydroxybenzoate (4). A mix-
ture of methyl 4-(dimethylamino)-2-hydroxy-5-iodobenzoate 3 (5.13
g, 16 mmol), compound 2 (6.5 g, 19 mmol), Na2CO3 (2.03 g, 19.2
mmol), bis(triphenylphosphine)palladium(II) chloride (0.576 g, 0.8
mmol), and CuI (304 mg, 1.6 mmol) were loaded in a ﬂask, which was
degassed and backﬁlled with nitrogen. then 15 mL of DMF were
added. The resulting mixture was stirred under a nitrogen atmosphere
at room temperature for 4 h. The reaction was monitored by TLC to
establish completion. The solution was partitioned between EtOAc
(200 mL) and brine (200 mL). The organic layers were washed with
brine (3 × 200 mL), dried over sodium sulfate, and concentrated in
vacuum. The residue was puriﬁed by ﬂash silica chromatography
(Hex/EtOAc = 4:1) to aﬀord titled compound as viscous oil (3.74 g,
44%). 1H NMR (500 MHz, CDCl3): δ 10.96 (s, 1H), 7.97 (s, 1H),
7.80 (m, 2H), 7.64 (m, 2H), 7.58 (brs, 1H), 7.45 (m, 2H), 7.20−7.31
(m, 6H), 6.72 (brs, 1H), 6.33 (s, 1H), 4.57 (d, J = 6.6 Hz, 2H), 4.30 (t,
J = 6.6 Hz, 1H), 3.93 (s, 3H), 3.15 (s, 6H). 13C NMR (125 MHz,
CDCl3): δ 169.8, 162.6, 159.2, 153.2, 153.2, 143.6, 141.3, 137.8, 137.4,
129.0, 127.8, 127.6, 127.1, 126.1, 124.9, 124.7, 120.7, 120.0, 104.1,
103.9, 102.8, 92.1, 89.0, 66.9, 51.9, 47.1, 42.5. HRMS (ESI): (M + H)+
calcd for C33H29N2O5, 533.2071; found, 533.2072. LC-MS (ESI):
533.2 (M + H)+, 530.8 (M −H)−. Purity: >95% (UV, λ = 254 nm).
Methyl 2-(3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-
phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylate (5).
To a solution of 4 (1.72 g, 3.23 mmol) and NaHCO3 (0.408 g,
4.85 mmol) in CH2Cl2 (500 mL) was added iodine (1.23 g, 4.85
mmol). The resulting mixture was stirred at room temperature for 4 h,
then 100 mL of CH2Cl2 was added, then washed with saturated
aqueous Na2SO3 solution (2 × 500 mL) and brine (500 mL), dried
over Na2SO4, and concentrated in vacuum. The residue was puriﬁed
by ﬂash chromatography (hexane/THF = 1:1) to aﬀord the title
compound as colorless solid (1.79 g, 86%); mp 131−132 °C. 1H NMR
(500 MHz, CDCl3): δ 10.92 (s, 1H), 8.03 (s, 1H), 7.79 (m, 2H), 7.65
(m, 2H), 7.48 (m, 5H), 7.36 (m, 2H), 7.18 (m, 1H), 6.85 (s, 1H), 6.80
(s, 1H), 4.61 (m, 2H), 4.30 (m, 1H), 4.03 (s, 3H), 3.60 (s, 3H). 13C
NMR (125 MHz, CDCl3): δ 171.2, 158.2, 153.4, 143.6, 142.5, 142.2,
141.3, 137.9, 131.9, 129.2, 127.8, 127.1, 127.0, 125.8, 124.8, 124.3,
124.1, 120.0, 107.6, 96.2, 66.9, 60.0, 52.3, 47.1, 32.1. HRMS (ESI): (M
+ H)+ calcd for C32H26IN2O5, 645.0881; found, 645.0851. LC-MS
(ESI): 667.0 (M + Na)+. Purity: >95% (UV, λ = 254 nm).
Methyl 2-(3-Aminophenyl)-6-hydroxy-3-iodo-1-methyl-1H-in-
dole-5-carboxylate (6). Compound 5 (1.79 g, 2.77 mmol) was
dissolved in 10 mL of CH2Cl2, and then 10 mL of diethylamine was
added to the solution under room temperature for 3 h. The solution
was concentrated in vacuum. The residue was partitioned between
CH2Cl2 (200 mL) and brine (200 mL). The organic layer was dried
over sodium sulfate and concentrated in vacuum. The residue was
puriﬁed by ﬂash silica chromatography (CH2Cl2 as elution) to aﬀord
the title compound as white solid (1 g, 85.5%); mp 83−85 °C. 1H
NMR (500 MHz, CDCl3): δ 10.90 (s, 1H), 8.02 (s, 1H), 7.31 (m,
1H), 6.84 (s, 1H), 6.80 (m, 2H), 6.76 (m, 1H), 4.03 (s, 3H), 3.83 (brs,
2H), 3.60 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 171.2, 158.1,
146.4, 143.1, 142.4, 132.1, 129.4, 124.2, 124.1, 120.8, 117.1, 115.6,
107.4, 96.1, 59.4, 52.1, 32.1. HRMS (ESI): (M + H)+ calcd for
C17H16IN2O3, 423.0200; found, 423.0190. LC-MS (ESI): 423.0 (M +
H)+, 420.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-Aminophenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-car-
boxylic Acid (7). Compound 6 (1 g, 2.37 mmol) was dissolved in 8
mL of THF. Then 5% LiOH (4 mL) solution was added. The mixture
was heated to 80 °C for 2 h, cooled to room temperature, diluted by
brine (200 mL), acidiﬁed by 2 N HCl to pH 5, and extracted with
EtOAc (2 × 200 mL). The organic layers were combined, washed with
brine, dried over sodium sulfate, and concentrated in vacuum to give
the title compound as pale solid (940 mg, 97.2%); decomposed at 148
°C. 1H NMR (500 MHz, DMSO): δ 7.85 (s, 1H), 7.46 (m, 1H), 7.11
(m, 3H), 7.04 (s, 1H), 4.11 (m, 2H), 3.59 (s, 3H). 13C NMR (125
MHz, DMSO): δ 173.0, 158.3, 142.6, 142.5, 140.9, 132.1, 130.0, 124.5,
124.0, 123.8, 120.9, 119.5, 108.1, 97.0, 60.6, 32.5. HRMS (ESI): (M −
H)− calcd for C16H12IN2O3, 406.9898; found, 406.9894. LC-MS
(ESI): 409.0 (M + H)+, 407.0 (M − H)−. Purity: >95% (UV, λ = 254
nm).
General Method for the Synthesis of 9a−d. Compound 7 (30
mg, 0.074 mmol) was dissolved in 1 mL of DMF under 0 °C, and then
1.5 equiv of corresponding acyl chloride 8a−d was added to the
solution for overnight. The solution was partitioned between EtOAc
(200 mL) and brine (200 mL). The organic layers were washed with
brine (3 × 200 mL), dried over sodium sulfate, and concentrated in
vacuum to aﬀord the title compounds as pale solids without
puriﬁcation for further use.
General Method for the Synthesis of 10a−d. Compound 9a−
d (0.074 mmol) was dissolved in 2 mL of THF. Then 5% LiOH (2
mL) solution was added. The mixture was stirred under room
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temperature for overnight, acidiﬁed by 2 N HCl to pH 5, and extracted
with EtOAc (2 × 200 mL). The organic layers were combined, washed
with brine, dried over sodium sulfate, and concentrated in vacuum.
This crude product was puriﬁed by Prep-HPLC to give the title
compounds.
2-(3-(Carboxyformamido)phenyl)-6-hydroxy-3-iodo-1-methyl-
1H-indole-5-carboxylic Acid (10a). Pale solid (26 mg, 71%, two
steps). 1H NMR (500 MHz, DMSO): δ 11.38 (brs, 1H), 10.95 (s,
1H), 7.94 (m, 2H), 7.86 (s, 1H), 7.54 (m, 1H), 7.30 (m, 1H), 7.05 (s,
1H), 3.61 (s, 3H). 13C NMR (125 MHz, DMSO): δ 173.0, 162.4,
158.3, 157.4, 142.5, 142.4, 138.3, 131.5, 129.4, 127.1, 124.0, 123.8,
122.6, 121.1, 108.1, 97.0, 60.8, 32.5. HRMS (ESI): (M − H)− calcd for
C18H12IN2O6, 478.9746; found, 478.9762. LC-MS (ESI): 481.0 (M +
H)+, 478.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-Carboxyacetamido)phenyl)-6-hydroxy-3-iodo-1-methyl-
1H-indole-5-carboxylic Acid (10b). Pale solid (30 mg, 82%, two
steps). 1H NMR (500 MHz, DMSO): δ 10.37 (s, 1H), 7.86 (s, 1H),
7.74 (m, 2H), 7.50 (m, 1H), 7.21 (m, 1H), 7.04 (s, 1H), 3.61 (s, 3H),
3.40 (s, 2H). HRMS (ESI): (M − H)− calcd for C19H14IN2O6,
492.9902; found, 492.9933. LC-MS (ESI): 495.0 (M + H)+, 492.8 (M
− H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(3-Carboxypropanamido)phenyl)-6-hydroxy-3-iodo-1-meth-
yl-1H-indole-5-carboxylic Acid (10c). Pale solid (31 mg, 82%, two
steps). 1H NMR (500 MHz, DMSO): δ 12.16 (brs, 1H), 11.36 (brs,
1H), 10.19 (s, 1H), 7.84 (s, 1H), 7.42 (m, 2H), 7.47 (s, 1H), 7.16 (m,
1H), 7.04 (s, 1H), 3.58 (s, 3H), 2.60 (m, 4H). 13C NMR (125 MHz,
DMSO): δ 174.2, 173.0, 170.8, 158.3, 142.8, 142.5, 139.9, 131.5, 129.4,
125.4, 123.9, 123.8, 121.2, 119.7, 108.0, 97.1, 60.6, 32.5, 31.5, 29.1.
HRMS (ESI): (M − H)− calcd for C20H16IN2O6, 507.0059; found,
507.0080. LC-MS (ESI): 509.0 (M + H)+, 507.0 (M − H)−. Purity:
>95% (UV, λ = 254 nm).
2-(3-(4-Carboxybutanamido)phenyl)-6-hydroxy-3-iodo-1-meth-
yl-1H-indole-5-carboxylic Acid (10d). Pale solid (21 mg, 54%, two
steps). 1H NMR (500 MHz, DMSO): δ 11.38 (brs, 1H), 10.12 (s,
1H), 7.85 (s, 1H), 7.74 (m, 2H), 7.48 (m, 1H), 7.17 (m, 1H), 7.04 (s,
1H), 3.59 (s, 3H), 2.40 (m, 2H), 2.29 (m, 2H), 1.83 (m, 2H). HRMS
(ESI): (M − H)− calcd for C21H18IN2O6, 521.0215; found, 520.9139.
LC-MS (ESI): 523.0 (M + H)+, 520.8 (M − H)−. Purity: >95% (UV, λ
= 254 nm).
Procedure for the Assembling of Library 11a−d. Compound
10a−d (65 mM, 3 μL) in DMF reacted with 192 amines (200 mM, 3
μL) in DMF respectively in the presence of HOBT (14 mM), HBTU
(17 mM), and DIPEA (28 mM) in 14 μL of DMF overnight to
assemble the combinatorial amide library 11a−d in 96-well plates. Ten
of the reactions were picked up randomly and monitored by LC-MS,
which showed an average of 70% yield desired products.
General Method for the Synthesis of (11a-1 to 11a-26 and
11c-1 to 11c-11). Compound 11a or 11c (0.02 mmol) dissolved in
0.5 mL of DMF was added to a solution of corresponding amines
(0.04 mmol), HOBT (3.06 mg, 0.02 mmol), HBTU (7.58 mg, 0.02
mmol), and DIPEA (5.16 μL, 0.04 mmol) in 1 mL of DMF. The
mixture was stirred under room temperature for 4 h. This crude
product was KJMM puriﬁed by Prep-HPLC to give titled compounds.
6-Hydroxy-3-iodo-1-methyl-2-(3-(2-oxo-2-((4-(thiophen-3-yl)-
phenyl)amino)acetamido)phenyl)-1H-indole-5-carboxylic Acid
(11a-1). Pale solid (3.8 mg, 29%); decomposed at 185 °C. 1H
NMR (500 MHz, DMSO): δ 11.08 (s, 1H), 10.95 (s, 1H), 8.06 (s,
1H), 8.01 (m, 1H), 7.92 (m, 2H), 7.85 (m, 2H), 7.75 (m, 2H), 7.63
(m, 1H), 7.57 (m, 2H), 7.33 (m, 1H), 7.06 (s, 1H), 3.63 (s, 3H). 13C
NMR (125 MHz, DMSO): δ 173.0, 159.2, 158.8, 158.3, 142.6, 142.5,
141.4, 138.3, 137.1, 132.0, 131.5, 129.5, 127.5, 127.2, 126.8, 126.5,
124.1, 123.9, 122.8, 121.3, 120.9, 108.1, 97.1, 60.9, 32.6. HRMS (ESI):
(M − H)− calcd for C28H19IN3O5S, 636.0096; found, 636.0098. LC-
MS (ESI): 659.8 (M + Na)+, 635.8 (M − H)−. Purity: >95% (UV, λ =
254 nm).
2-(3-(2-([1,1′-Biphenyl]-4-ylamino)-2-oxoacetamido)phenyl)-6-
hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-2). Pale
solid (3.5 mg, 27%). 1H NMR (500 MHz, DMSO): δ 11.11 (s, 1H),
11.02 (s, 1H), 8.08 (s, 1H), 8.03 (m, 1H), 7.99 (m, 2H), 7.87 (s, 1H),
7.70 (m, 4H), 7.59 (m, 1H), 7.37 (m, 2H), 7.33 (m, 2H), 7.06 (s, 1H),
3.64 (s, 3H). HRMS (ESI): (M − H)− calcd for C30H21IN3O5,
630.0531; found, 630.0546. LC-MS (ESI): 653.8 (M + Na)+, 629.8 (M
− H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-((4-(Benzyloxy)-3-chlorophenyl)amino)-2-oxoacetamido)-
phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid
(11a-3). Pale solid (4.2 mg, 30%). 1H NMR (500 MHz, DMSO): δ
11.37 (s, 1H), 11.07 (s, 1H), 10.97 (s, 1H), 8.04 (m, 2H), 7.93 (m,
1H), 7.86 (s, 1H), 7.80 (m, 1H), 7.59−7.27 (m, 8H), 7.07 (s, 1H),
6.82 (m, 1H), 5.21 (s, 2H), 3.63 (s, 3H). HRMS (ESI): (M − H)−
calcd for C31H22ClIN3O6, 694.0247; found, 694.0233. LC-MS (ESI):
718.0 (M + Na)+, 693.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-((6-Bromobenzo[d]thiazol-2-yl)amino)-2-oxoacetamido)-
phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid
(11a-4). Pale solid (3.4 mg, 24%). 1H NMR (500 MHz, DMSO): δ
13.16 (s, 1H), 11.37 (s, 1H), 11.27 (s, 1H), 8.37 (s, 1H), 8.02 (m,
2H), 7.87 (s, 1H), 7.78 (m, 1H), 7.63 (m, 2H), 7.34 (m, 1H), 7.07 (s,
1H), 3.63 (s, 3H). HRMS (ESI): (M − H)− calcd for
C25H15BrIN4O5S, 688.8997; found, 688.9008. LC-MS (ESI): 690.6
(M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-([1,1′-Biphenyl]-3-ylamino)-2-oxoacetamido)phenyl)-6-
hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-5). Pale
solid (4.5 mg, 35%). 1H NMR (500 MHz, DMSO): δ 11.37 (s, 1H),
11.12 (s, 1H), 10.99 (s, 1H), 8.23 (s, 1H), 8.05 (m, 2H), 7.90 (m,
1H), 7.87 (s, 1H), 7.80 (m, 1H), 7.65 (m, 3H), 7.52 (m, 6H), 7.08 (s,
1H), 3.63 (s, 3H). HRMS (ESI): (M − H)− calcd for C30H21IN3O5,
630.0531; found, 630.0533. LC-MS (ESI): 629.8 (M − H)−. Purity:
>95% (UV, λ = 254 nm).
2-(3-(2-((3-(Benzyloxy)phenyl)amino)-2-oxoacetamido)phenyl)-
6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-6).
Pale solid (3.6 mg, 27%). 1H NMR (500 MHz, DMSO): δ 11.38 (s,
1H), 11.09 (s, 1H), 10.86 (s, 1H), 8.06 (s, 1H), 8.00 (m, 1H), 7.86 (s,
1H), 7.64 (s, 1H), 7.58−7.27 (m, 9H), 7.07 (s, 1H), 6.82 (m, 1H),
5.10 (s, 2H), 3.63 (s, 3H). HRMS (ESI): (M − H)− calcd for
C31H23IN3O6, 660.0637; found, 660.0627. LC-MS (ESI): 684.0 (M +
Na)+, 659.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-(5-Bromoindolin-1-yl)-2-oxoacetamido)phenyl)-6-hy-
droxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-7). Pale
solid (4.6 mg, 34%). 1H NMR (500 MHz, DMSO): δ 11.36 (s, 1H),
11.09 (s, 1H), 8.06 (m, 1H), 7.92 (m, 1H), 7.89 (s, 1H), 7.86 (s, 1H),
7.57 (m, 2H), 7.46 (m, 1H), 7.31 (m, 1H), 7.07 (s, 1H), 4.39 (m, 2H),
3.64 (s, 3H), 3.18 (m, 2H). HRMS (ESI): (M − H)− calcd for
C26H18BrIN3O5, 657.9480; found, 657.9501.; LC-MS (ESI): 661.8 (M
+ H)+, 659.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
6-Hydroxy-3- iodo-2 - (3 - (2 - ( (4 - iodopheny l )amino) -2 -
oxoacetamido)phenyl)-1-methyl-1H-indole-5-carboxylic Acid (11a-
8). Pale solid (3.5 mg, 25%). 1H NMR (500 MHz, DMSO): δ 11.36
(s, 1H), 11.08 (s, 1H), 11.01 (s, 1H), 8.05 (s, 1H), 8.01 (m, 1H), 7.86
(s, 1H), 8.01 (m, 1H), 7.73 (m, 4H), 7.58 (m, 1H), 7.33 (m, 1H), 7.07
(s, 1H), 3.63 (s, 3H). HRMS (ESI): (M − H)− calcd for
C24H16I2N3O5, 679.9185; found, 679.9183. LC-MS (ESI): 703.8 (M
+ Na)+, 679.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-((2-(1H-Benzo[d]imidazol-2-yl)phenyl)amino)-2-
oxoacetamido)phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-
carboxylic Acid (11a-9). Pale solid (4.7 mg, 35%). 1H NMR (500
MHz, DMSO): δ 11.38 (s, 1H), 11.13 (s, 1H), 8.81 (m, 1H), 8.17 (m,
1H), 8.12 (s, 2H), 7.78 (s, 1H), 7.64 (m, 4H), 7.39 (m, 5H), 7.07 (s,
1H), 3.64 (s, 3H). HRMS (ESI): (M − H)− calcd for C31H21IN5O5,
670.0593; found, 670.0594. LC-MS (ESI): 672.0 (M + H)+, 669.8 (M
− H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-(Benzo[d]thiazol-2-ylamino)-2-oxoacetamido)phenyl)-6-
hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-10).
Pale solid (3.5 mg, 28%). 1H NMR (500 MHz, DMSO): δ 13.02 (s,
1H), 11.37 (s, 1H), 11.28 (s, 1H), 8.12 (m, 1H), 8.06 (s, 2H), 7.85
(m, 2H), 7.60 (m, 1H), 7.52 (m, 1H), 7.38 (m, 2H), 7.06 (s, 1H), 3.63
(s, 3H). HRMS (ESI): (M − H)− calcd for C25H16IN4O5S, 610.9892;
found, 610.9884. LC-MS (ESI): 613.0 (M + H)+, 610.8 (M − H)−.
Purity: >95% (UV, λ = 254 nm).
2-(3-(2-((3-Chlorophenyl)amino)-2-oxoacetamido)phenyl)-6-hy-
droxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-11). Pale
solid (4.1 mg, 34%). 1H NMR (500 MHz, DMSO): δ 11.36 (s, 1H),
11.11 (s, 1H), 11.10 (s, 1H), 8.03 (m, 3H), 7.85 (m, 2H), 7.57 (m,
1H), 7.42 (m, 1H), 7.34 (m, 1H), 7.24 (m, 1H), 7.07 (s, 1H), 3.63 (s,
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3H). HRMS (ESI): (M − H)− calcd for C24H16ClIN3O5, 587.9829;
found, 587.9831. LC-MS (ESI): 587.8 (M − H)−. Purity: >95% (UV,
λ = 254 nm).
2-(3-(2-((4-(1H-Imidazol-1-yl)phenyl)amino)-2-oxoacetamido)-
phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid
(11a-12). Pale solid (4.8 mg, 38%). 1H NMR (500 MHz, DMSO):
δ 11.24 (s, 1H), 11.15 (s, 1H), 9.53 (s, 1H), 8.23 (s, 1H), 8.13 (m,
2H), 8.08 (s, 1H), 8.01 (m, 1H), 7.87 (s, 1H), 7.82 (m, 3H), 7.59 (m,
1H), 7.35 (m, 1H), 7.08 (s, 1H), 3.63 (s, 3H). HRMS (ESI): (M −
H)− calcd for C27H19IN5O5, 620.0436; found, 620.0442. LC-MS
(ESI): 622.0 (M + H)+, 619.8 (M − H)−. Purity: >95% (UV, λ = 254
nm).
2-(3-(2-((4-Chloro-3-(triﬂuoromethyl)phenyl)amino)-2-
oxoacetamido)phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-
carboxylic Acid (11a-13). Pale solid (3.6 mg, 27%). 1H NMR (500
MHz, DMSO): δ 11.38 (s, 2H), 11.14 (s, 1H), 10.99 (s, 1H), 8.52 (s,
1H), 8.19 (m, 1H), 8.06 (s, 1H), 8.01 (m, 1H), 7.86 (s, 1H), 7.77 (m,
1H), 7.59 (m, 1H), 7.34 (m, 1H), 7.07 (s, 1H), 3.63 (s, 3H). HRMS
(ESI): (M − H)− calcd for C25H15ClF3IN3O5, 655.9702; found,
655.9720. LC-MS (ESI): 679.8 (M + Na)+, 655.8 (M − H)−. Purity:
>95% (UV, λ = 254 nm).
6-Hydroxy-3-iodo-1-methyl-2-(3-(2-oxo-2-((5-phenyl-1,3,4-thia-
diazol-2-yl)amino)acetamido)phenyl)-1H-indole-5-carboxylic Acid
(11a-14). Pale solid (4.5 mg, 35%). 1H NMR (500 MHz, DMSO):
δ 13.61 (s, 1H), 11.38 (s, 1H), 11.29 (s, 1H), 8.01 (m, 4H), 7.86 (s,
1H), 7.58 (m, 4H), 7.34 (m, 4H), 7.07 (s, 1H), 3.62 (s, 3H). HRMS
(ESI): (M − H)− calcd for C26H17ClIN5O5S, 638.0001; found,
638.0015. LC-MS (ESI): 637.8 (M − H)−. Purity: >95% (UV, λ = 254
nm).
2-(3-(2-((4-Fluorophenyl)amino)-2-oxoacetamido)phenyl)-6-hy-
droxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-15). Pale
solid (4.7 mg, 41%). 1H NMR (500 MHz, DMSO): δ 11.39 (s, 1H),
11.11 (s, 1H), 11.02 (s, 1H), 8.06 (s, 1H), 8.01 (m, 1H), 7.92 (m,
2H), 7.88 (s, 1H), 7.58 (m, 1H), 7.34 (m, 1H), 7.23 (m, 2H), 7.06 (s,
1H), 3.63 (s, 3H). HRMS (ESI): (M − H)− calcd for C24H16FIN3O5,
572.0124; found, 572.0148. LC-MS (ESI): 571.8 (M − H)−. Purity:
>95% (UV, λ = 254 nm).
6-Hydroxy-3-iodo-1-methyl-2-(3-(2-oxo-2-(thiazol-2-ylamino)-
acetamido)phenyl)-1H-indole-5-carboxylic Acid (11a-16). Pale solid
(3.9 mg, 34%). 1H NMR (500 MHz, DMSO): δ 12.73 (s, 1H), 11.36
(s, 1H), 11.20 (s, 1H), 8.01 (s, 1H), 7.99 (s, 1H), 7.86 (s, 1H), 7.60
(m, 2H), 7.42 (m, 1H), 7.32 (m, 1H), 7.07 (s, 1H), 3.62 (s, 3H).
HRMS (ESI): (M − H)− calcd for C21H14IN4O5S, 560.9735; found,
560.9744. LC-MS (ESI): 563.0 (M + H)+, 560.8 (M − H)−. Purity:
>95% (UV, λ = 254 nm).
6-Hydroxy-3-iodo-1-methyl-2-(3-(2-oxo-2-((3-(triﬂuoromethoxy)-
phenyl)amino)acetamido)phenyl)-1H-indole-5-carboxylic Acid
(11a-17). Pale solid (3.3 mg, 25%). 1H NMR (500 MHz, DMSO):
δ 11.37 (s, 1H), 11.21 (s, 1H), 11.13 (s, 1H), 8.05 (m, 3H), 7.90 (m,
1H), 7.87 (s, 1H), 7.76−7.51 (m, 2H), 7.33 (m, 1H), 7.17 (m, 1H),
7.07 (s, 1H), 3.63 (s, 3H). HRMS (ESI): (M − H)− calcd for
C25H16F3IN3O6, 638.0041; found, 638.0039. LC-MS (ESI): 661.8 (M
+ Na)+, 637.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-((3-Bromophenyl)amino)-2-oxoacetamido)phenyl)-6-hy-
droxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-18). Pale
solid (3.8 mg, 30%). 1H NMR (500 MHz, DMSO): δ 11.38 (s, 1H),
11.10 (s, 1H), 11.08 (s, 1H), 8.17 (s, 1H), 8.06 (s, 1H), 8.01 (m, 1H),
7.89 (m, 1H), 7.86 (s, 1H), 7.58 (m, 1H), 7.36 (m, 3H), 7.07 (s, 1H),
3.63 (s, 3H). HRMS (ESI): (M − H)− calcd for C24H16BrIN3O5,
631.9323; found, 631.9326. LC-MS (ESI): 655.8 (M + Na)+, 631.8 (M
− H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-((3-Fluorophenyl)amino)-2-oxoacetamido)phenyl)-6-hy-
droxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-19). Pale
solid (4.7 mg, 41%). 1H NMR (500 MHz, DMSO): δ 11.37 (s, 1H),
11.13 (s, 2H), 8.08 (s, 1H), 8.03 (m, 1H), 7.99 (m, 2H), 7.87 (s, 1H),
7.82 (m, 1H), 7.76 (m, 1H), 7.58 (m, 1H), 7.43 (m, 1H), 7.32 (m,
1H), 7.06 (s, 1H), 7.01 (m, 1H), 3.64 (s, 3H). HRMS (ESI): (M −
H)− calcd for C24H16FIN3O5, 572.0124; found, 572.0136. LC-MS
(ESI): 573.8 (M + H)+, 571.8 (M − H)−. Purity: >95% (UV, λ = 254
nm).
6-Hydroxy-3- iodo-2 - (3 - (2 - ( (3 - iodopheny l )amino) -2 -
oxoacetamido)phenyl)-1-methyl-1H-indole-5-carboxylic Acid (11a-
20). Pale solid (4.5 mg, 33%). 1H NMR (500 MHz, DMSO): δ 11.36
(s, 1H), 11.08 (s, 1H), 11.01 (s, 1H), 8.34 (s, 1H), 8.05 (s, 1H), 8.01
(m, 1H), 8.01 (m, 1H), 7.90 (m, 1H), 7.87 (s, 1H), 7.57 (m, 2H), 7.33
(m, 1H), 7.19 (m, 1H), 7.07 (s, 1H), 3.63 (s, 3H). HRMS (ESI): (M
− H)− calcd for C24H16I2N3O5, 679.9185; found, 679.9184. LC-MS
(ESI): 679.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-((4′-Cyano-[1,1′-biphenyl]-4-yl)amino)-2-oxoacetamido)-
phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid
(11a-21). Pale solid (2.3 mg, 17%). 1H NMR (500 MHz, DMSO):
δ 11.37 (s, 1H), 11.12 (s, 1H), 11.10 (s, 1H), 8.14−8.04 (m, 4H), 7.93
(m, 4H), 7.87−7.81 (m, 3H), 7.59 (m, 1H), 7.35 (m, 1H), 7.07 (s,
1H), 3.64 (s, 3H). HRMS (ESI): (M − H)− calcd for C31H20IN4O5,
655.0484; found, 655.0509. LC-MS (ESI): 654.8 (M − H)−. Purity:
>95% (UV, λ = 254 nm).
2-(3-(2-((3′-Cyano-[1,1′-biphenyl]-4-yl)amino)-2-oxoacetamido)-
phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid
(11a-22). Pale solid (2.9 mg, 21%). 1H NMR (500 MHz, DMSO):
δ 11.37 (s, 1H), 11.11 (s, 1H), 11.07 (s, 1H), 8.18 (s, 1H), 8.03 (m,
5H), 7.87 (s, 1H), 7.82 (m, 3H), 7.67 (m, 1H), 7.59 (m, 1H), 7.34 (m,
1H), 7.08 (s, 1H), 3.64 (s, 3H). HRMS (ESI): (M − H)− calcd for
C31H20IN4O5, 655.0484; found, 655.0499. LC-MS (ESI): 654.8 (M −
H)−. Purity: >95% (UV, λ = 254 nm).
6-Hydroxy-2-(3-(2-((2-(5-(hydroxymethyl)furan-2-yl)phenyl)-
amino)-2-oxoacetamido)phenyl)-3-iodo-1-methyl-1H-indole-5-car-
boxylic Acid (11a-23). Pale solid (2.4 mg, 18%). 1H NMR (500 MHz,
DMSO): δ 11.15 (s, 1H), 10.76 (s, 1H), 8.05 (m, 3H), 7.87 (s, 1H),
7.82 (s, 1H), 7.76 (m, 1H), 7.58 (m, 2H), 7.41 (m, 3H), 7.08 (s, 1H),
4.51 (s, 2H), 3.65 (s, 1H), 3.64 (s, 3H). HRMS (ESI): (M − H)−
calcd for C29H21IN3O7, 650.0430; found, 650.0422. LC-MS (ESI):
649.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-((3-(Furan-2-yl)phenyl)amino)-2-oxoacetamido)phenyl)-
6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11a-24).
Pale solid (4.6 mg, 37%). 1H NMR (500 MHz, DMSO): δ 11.36 (s,
1H), 11.10 (s, 1H), 10.98 (s, 1H), 8.29 (s, 1H), 8.07 (s, 1H), 8.03 (m,
1H), 7.94 (m, 1H), 7.87 (s, 1H), 7.77 (m, 2H), 7.50 (m, 4H), 7.34 (m,
1H), 7.07 (s, 1H), 6.90 (m, 1H), 3.64 (s, 3H). HRMS (ESI): (M −
H)− calcd for C28H19IN3O6, 620.0324; found, 620.0327. LC-MS
(ESI): 619.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(2-((4′-Cyano-[1,1′-biphenyl]-3-yl)amino)-2-oxoacetamido)-
phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid
(11a-25). Pale solid (3.4 mg, 26%). 1H NMR (500 MHz, DMSO):
δ 11.12 (s, 1H), 11.05 (s, 1H), 8.29 (s, 1H), 8.08 (s, 1H), 8.03 (m,
4H), 7.87 (s, 1H), 7.86 (s, 1H), 7.56 (m, 3H), 7.33 (m, 1H), 7.09 (s,
1H), 3.64 (s, 3H). HRMS (ESI): (M − H)− calcd for C31H20IN4O5,
655.0484; found, 655.0485. LC-MS (ESI): 654.8 (M − H)−. Purity:
>95% (UV, λ = 254 nm).
6-Hydroxy-3-iodo-1-methyl-2-(3-(2-oxo-2-((3-(thiophen-3-yl)-
phenyl)amino)acetamido)phenyl)-1H-indole-5-carboxylic Acid
(11a-26). Pale solid (3.1 mg, 24%). 1H NMR (500 MHz, DMSO):
δ 11.12 (s, 1H), 10.92 (s, 1H), 8.22 (s, 1H), 8.08 (s, 1H), 8.02 (m,
4H), 7.87 (s, 1H), 7.84 (m, 2H), 7.68 (m, 1H), 7.59 (m, 1H), 7.52 (m,
2H), 7.43 (m, 1H), 7.34 (m, 1H), 7.08 (s, 1H), 3.64 (s, 3H). HRMS
(ESI): (M − H)− calcd for C28H19IN3O5S, 636.0096; found, 636.0102.
LC-MS (ESI): 635.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
6-Hydroxy-3-iodo-1-methyl-2-(3-(4-oxo-4-((4-(thiophen-3-yl)-
phenyl)amino)butanamido)phenyl)-1H-indole-5-carboxylic Acid
(11c-1). Pale solid (3.8 mg, 28%). 1H NMR (500 MHz, DMSO): δ
11.35 (brs, 1H), 10.24 (s, 1H), 10.08 (s, 1H), 7.86 (s, 1H), 7.73 (m,
4H), 7.62 (m, 4H), 7.52 (m, 3H), 7.17 (m, 1H), 7.04 (s, 1H), 3.56 (s,
3H), 2.69 (m, 4H). HRMS (ESI): (M − H)− calcd for C30H23IN3O5S,
664.0409; found, 664.0414. LC-MS (ESI): 663.8 (M − H)−. Purity:
>95% (UV, λ = 254 nm).
6-Hydroxy-3-iodo-1-methyl-2-(3-(4-oxo-4-((4-phenoxyphenyl)-
amino)butanamido)phenyl)-1H-indole-5-carboxylic Acid (11c-2).
Pale solid (1.6 mg, 11%). 1H NMR (500 MHz, DMSO): δ 10.22 (s,
1H), 10.04 (s, 1H), 7.83 (s, 1H), 7.76 (m, 2H), 7.60 (m, 2H), 7.47
(m, 1H), 7.35 (m, 2H), 7.09 (m, 3H), 6.96 (m, 4H), 3.58 (s, 3H), 2.67
(m, 4H). HRMS (ESI): (M − H)− calcd for C32H25IN3O6, 674.0794;
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found, 664.0796. LC-MS (ESI): 673.8 (M − H)−. Purity: >95% (UV,
λ = 254 nm).
2 - ( 3 - ( 4 - ( ( 4 - ( B en z y l o x y ) - 3 - ch l o r opheny l ) am ino ) - 4 -
oxobutanamido)phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-
carboxylic Acid (11c-3). Pale solid (5.7 mg, 39%). 1H NMR (500
MHz, DMSO): δ 10.23 (s, 1H), 10.03 (s, 1H), 7.84 (s, 1H), 7.80 (m,
2H), 7.49−7.33 (m, 8H), 7.17 (m, 2H), 7.03 (s, 1H), 5.15 (s, 2H),
3.58 (s, 3H), 2.67 (m, 4H). HRMS (ESI): (M − H)− calcd for
C33H26ClIN3O6, 722.0560; found, 722.0563. LC-MS (ESI): 746.0 (M
+ Na)+, 721.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(4-((3-(Benzyloxy)phenyl)amino)-4-oxobutanamido)-
phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid
(11c-4). Pale solid (2.2 mg, 15%). 1H NMR (500 MHz, DMSO): δ
11.35 (brs, 1H), 10.22 (s, 1H), 9.99 (s, 1H), 7.84 (s, 1H), 7.73 (m,
2H), 7.50−7.32 (m, 7H), 7.15 (m, 3H), 7.04 (s, 1H), 6.68 (m, 1H),
5.05 (s, 2H), 3.58 (s, 3H), 2.67 (m, 4H). HRMS (ESI): (M − H)−
calcd for C33H27IN3O6, 688.0950; found, 688.0950. LC-MS (ESI):
687.8 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(4-([1,1′-Biphenyl]-3-ylamino)-4-oxobutanamido)phenyl)-6-
hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11c-5). Pale
solid (4.8 mg, 36%). 1H NMR (500 MHz, DMSO): δ 11.35 (brs, 1H),
10.24 (s, 1H), 10.12 (s, 1H), 7.93 (m, 2H), 7.84 (s, 1H), 7.76 (m,
2H), 7.60−7.40 (m, 8H), 7.16 (m, 1H), 7.03 (s, 1H), 3.58 (s, 3H),
2.64 (m, 4H). HRMS (ESI): (M − H)− calcd for C32H25IN3O5,
658.0844; found, 658.0861. LC-MS (ESI): 683.4 (M + H)+, 657.8 (M
− H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(4-(5-Bromoindolin-1-yl)-4-oxobutanamido)phenyl)-6-hy-
droxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid (11c-6). Pale
solid (3.2 mg, 23%). 1H NMR (500 MHz, DMSO): δ 11.35 (brs,
1H), 10.25 (s, 1H), 7.97 (m, 1H), 7.84 (s, 1H), 7.76 (m, 2H), 7.47
(m, 1H), 7.42 (s, 1H), 7.29 (m, 1H), 7.17 (m, 1H), 7.04 (s, 1H), 4.16
(m, 2H), 3.56 (s, 3H), 3.17 (m, 2H), 2.77 (m, 2H), 2.71 (m, 2H).
HRMS (ESI): (M − H)− calcd for C28H22BrIN3O5, 685.9793; found,
685.9798. LC-MS (ESI): 687.8 (M − H)−. Purity: >95% (UV, λ = 254
nm).
6-Hydroxy-3-iodo-1-methyl-2-(3-(4-oxo-4-((4-(triﬂuoromethoxy)-
phenyl)amino)butanamido)phenyl)-1H-indole-5-carboxylic Acid
(11c-7). Pale solid (6.1 mg, 45%). 1H NMR (500 MHz, DMSO): δ
11.35 (brs, 1H), 10.23 (s, 1H), 10.22 (s, 1H), 7.84 (s, 1H), 7.71 (m,
5H), 7.48 (m, 1H), 7.30 (m, 2H), 7.16 (m, 1H), 7.03 (s, 1H), 3.58 (s,
3H), 2.70 (m, 4H). HRMS (ESI): (M − H)− calcd for
C27H20F3IN3O6, 666.0354; found, 666.0329. LC-MS (ESI): 665.8
(M − H)−. Purity: >95% (UV, λ = 254 nm).
6-Hydroxy-3-iodo-2-(3-(4-((4-isopropylphenyl)amino)-4-
oxobutanamido)phenyl)-1-methyl-1H-indole-5-carboxylic Acid
(11c-8). Pale solid (2.1 mg, 16%). 1H NMR (500 MHz, DMSO): δ
9.91 (s, 1H), 7.70 (s, 1H), 7.50−7.45 (m, 5H), 7.15 (m, 5H), 6.66 (s,
1H), 3.58 (s, 3H), 2.82 (m, 1H), 2.64 (m, 4H), 1.17 (d, J = 6.9 Hz,
1H). HRMS (ESI): (M − H)− calcd for C29H27IN3O5, 624.1001;
found, 624.1037. LC-MS (ESI): 648.0 (M + Na)+, 624.0 (M − H)−.
Purity: >95% (UV, λ = 254 nm).
2 - (3 - (4 - ( ( Benzo [d ] [1 ,3 ]d ioxo l -5 -y lmethy l )amino ) -4 -
oxobutanamido)phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-
carboxylic Acid (11c-9). Pale solid (8.1 mg, 63%). 1H NMR (500
MHz, DMSO): δ 11.35 (brs, 1H), 10.19 (s, 1H), 8.37 (m, 1H), 7.85
(s, 1H), 7.61 (s, 1H), 7.72 (m, 1H), 7.47 (m, 1H), 7.16 (m, 1H), 7.03
(s, 1H), 6.80 (m, 2H), 6.70 (m, 1H), 5.93 (s, 2H), 4.17 (m, 2H), 3.58
(s, 3H), 2.64 (m, 4H). 13C NMR (125 MHz, DMSO): δ 172.8, 171.8,
171.3, 158.2, 147.6, 146.3, 142.9, 142.5, 139.8, 133.9, 131.5, 129.4,
125.5, 123.9, 123.8, 121.2, 120.7, 119.8, 108.3, 108.2, 108.0, 101.1,
97.0, 60.5, 42.2, 32.5, 32.0, 30.6. HRMS (ESI): (M − H)− calcd for
C28H23IN3O7, 640.0586; found, 640.0569. LC-MS (ESI): 642.0 (M +
H)+, 639.6 (M − H)−. Purity: >95% (UV, λ = 254 nm).
2-(3-(4-((Cyclopropylmethyl)(propyl)amino)-4-oxobutanamido)-
phenyl)-6-hydroxy-3-iodo-1-methyl-1H-indole-5-carboxylic Acid
(11c-10). Pale solid (10.6 mg, 87%). 1H NMR (500 MHz, DMSO):
δ 11.35 (brs, 1H), 10.16 (s, 1H), 7.85 (s, 1H), 7.73 (m, 2H), 7.48 (m,
1H), 7.16 (m, 1H), 7.04 (s, 1H), 3.58 (s, 3H), 3.33−3.14 (m, 4H),
2.64 (m, 2H), 1.59−1.46 (m, 2H), 0.88 (m, 4H), 0.50−0.10 (m, 4H).
HRMS (ESI): (M − H)− calcd for C27H29IN3O5, 602.1157; found,
602.1171. LC-MS (ESI): 604.0 (M + H)+, 602.0 (M − H)−. Purity:
>95% (UV, λ = 254 nm).
6-Hydroxy-3-iodo-1-methyl-2-(3-(4-oxo-4-(thiazol-2-ylamino)-
butanamido)phenyl)-1H-indole-5-carboxylic Acid (11c-11). Pale
solid (0.9 mg, 7%). 1H NMR (500 MHz, DMSO): δ 12.15 (s, 1H),
10.25 (s, 1H), 7.84 (s, 1H), 7.74 (m, 2H), 7.46 (m, 3H), 7.17 (m,
3H), 6.88 (s, 1H), 3.58 (s, 3H), 2.64 (m, 4H). HRMS (ESI): (M −
H)− calcd for C23H18IN4O5S, 589.0048; found, 589.0056. LC-MS
(ESI): 591.0 (M + H)+. Purity: >95% (UV, λ = 254 nm).
SHP2 Crystallization and X-ray Data Collection. Recombinant
SHP2 expression and puriﬁcation were described previously.35 All
crystallization experiments were performed at room temperature using
the sitting drop vapor diﬀusion method. For co-crystallization, 100 μL
of SHP2 stock (7.0 mg/mL) in 20 mM MES (pH 6.0), 50 mM NaCl,
0.1 mM EDTA, and 4 mM DTT was mixed with 1 μL of compound
11a-1 or 11c-9 stock solution (50 mM in DMSO). Crystals of SHP2·
11c-9 complex were obtained at room temperature by vapor diﬀusion
in sitting drops. Protein drops were equilibrated against a reservoir
solution containing 20% w/v polyethylene glycol 3350, 200 mM
magnesium acetate tetrahydrate, and 100 mM HEPES buﬀer (pH 7.7).
For X-ray data collection, the crystals were transferred into 4 μL of
cryoprotectant buﬀer containing 30% w/v polyethylene glycol 3350,
100 mM NaCl, 1 mM 11c-9, and 100 mM HEPES (pH 7.7) and were
allowed to soak for 30 min. The crystals were then ﬂash-cooled by
liquid nitrogen. X-ray data were collected at 19 μB beamline at APS
(Argonne, IL). Data were processed using the program HKL3000.64
The space group of the crystals is P1. The statistics are provided in
Table 5.
Structural Determination and Reﬁnement. The structure of
SHP2·11c-9 was solved by molecular replacement using the program
MolRep.65 The structure of SHP2 (PDB: 3B7O),52 without the
solvent molecules, was used as a search model. The resulting diﬀerence
Fourier map indicated the ﬁrst 16 N-terminal residues has diﬀerent
conformation. The map also revealed the density for the compound
11c-9 in the active site of SHP2. The N-terminal peptide 246−261 was
ﬁrst rebuilt according to the Fo − Fc density map, then the structure
was reﬁned to 2.4 Å resolution with the program CNS1.1,66 using
simulated annealing at 2500 K and then alternating positional and
individual temperature factor reﬁnement cycles. The density in the
active site was interpreted to be 11c-9. Then alternating positional and
individual temperature factor reﬁnement cycles were applied to the
structure. The progress of the reﬁnement was evaluated by
improvement in the quality of the electron density maps, and the
reduced values of the conventional R factor (R = ∑h||Fo| − |Fc||/∑h|
Fo|) and the free R factor (3.7% of the reﬂections omitted from the
reﬁnement).67 Electron density maps were inspected, and the model
was modiﬁed on Coot.68 Finally, water molecules were added
gradually as the reﬁnement progressed. They were assigned in the |
Fo| − |Fc| diﬀerence Fourier maps with a 2.5σ cutoﬀ level for inclusion
in the model.
Docking Studies. The 3D structure of 11a-1 was built and energy-
minimized using Chem3D program, and three SHP2 catalytic domain
structures, 3B7O.pdb52 (apo form SHP2 catalytic domain),
3O5X.pdb35 (SHP2·II-B08 complex structure) and 4PVG.pdb
(SHP2·11c-9 complex structure), were used for ensemble docking
in the AutoDock4.2.5 software suite.69 The ligand and receptor were
predocking processed as following in AutoDockTools1.4.6 program:70
merge nonpolar hydrogens, add Gasteiger charges, set rotatable bond
for ligand, add solvation parameter for receptor, and so on. To deﬁne
the common docking area, the above two SHP2 complex structures
were superimposed onto the apo form of SHP2, a rectangle docking
area was visually set to adequately cover both II-B08 and 11c-9 around
the active site, the energy grid size was set to 54 × 54 × 36 points with
0.375 Å spacing on each axis, and the energy grid maps for each atom
type (i.e., A, C, I, OA, N, SA, and HD), as well as the electrostatics and
desolvation maps were calculated using the AutoGrid4. The molecular
docking were carried out using AutoDock4.2.5, the optimal binding
conformation was determined by LGALS (Lamarckian Genetic
Algorithm with Local Search) algorithm with the following parameters
during each docking run: energy evaluations of 2500000, population
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size of 100, mutation rate of 0.02, crossover rate of 0.8, Solis and Wets
local search iterations of 300 with probability of 0.06. For each SHP2
structure, 200 docking runs were performed and the resulted binding
modes were conformation-clustered and energy-ranked. The ﬁnal
binding mode was determined by visual inspections, cluster analyses,
and energy comparisons.
Inhibition Studies. The phosphatase activity of SHP2 was assayed
using p-nitrophenyl phosphate (pNPP) as a substrate at 25 °C in 50
mM 3,3-dimethylglutarate buﬀer, pH 7.0, containing 1 mM EDTA
with an ionic strength of 0.15 M adjusted by NaCl. The hydroxyindole
carboxylic acid-based libraries were screened in a 384-well format at 5
μM compound concentration. The reaction was initiated by the
addition of 20 μL of the enzyme to 30 μL of reaction mixture
containing 5 μM library compound and 2.9 mM (the Km value) pNPP
and quenched after 10 min by the addition of 20 μL of 5N NaOH.
The nonenzymatic hydrolysis of pNPP was corrected by measuring the
control without the addition of enzyme. The amount of product p-
nitrophenol was determined from the absorbance at 405 nm detected
by a Spectra MAX340 microplate spectrophotometer (Molecular
Devices) using a molar extinction coeﬃcient of 18000 M−1cm−1.
Inhibitor concentrations used for IC50 measurements cover the range
from 0.2 to 5× of the IC50 value. IC50 values for selected resynthesized
and puriﬁed hits were calculated by ﬁtting the absorbance at 405 nm
versus inhibitor concentration to the following equation:
= +A A/ IC /(IC [I])I 0 50 50
where AI is the absorbance at 405 nm of the sample in the presence of
inhibitor, A0 is the absorbance at 405 nm in the absence of inhibitor,
and [I] is the concentration of the inhibitor.
For selectivity studies, the PTPs, including LYP, HePTP, PTPH1,
SHP1, Ssu72, PTP1B, LMWPTP, VHZ, PTPγ, MKP5, VHR, PTPμ,
STEP, PEZ, PTPσ, UBLCP1, Laforin, CDC14A, PTPε, and PTPα,
were expressed and puriﬁed from Escherichia coli. The IC50
determination for these PTPs was performed under the same
conditions as for SHP2, except the pNPP concentrations used
corresponded to the Km values of the PTPs studied.
Eﬀects of SHP2 Inhibitor 11a-1 on Lung Cancer Cell Line
H1975. Human nonsmall cell lung carcinoma cell line H1975 was
obtained from the American Tissue Culture Collection and cultured at
37 °C and 5% CO2 in RPMI-1640 (Corning) supplemented with 10%
fetal bovine serum (HyClone). 3 ×103 cells were seeded in each well
of 96-well plates. After treatment with 11a-1 for 2 days in RPMI-1640
supplement with 0.5% FBS, cells were incubated with 50 μg/mL MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
(Sigma) for 3−4 h. Then the culture medium was removed, and
DMSO was added to dissolve the formazan crystals. Wells containing
only media were used for background correction. The optical density
was measured spectrophotometrically at 540 nm. For biochemical
studies, H1975 cells were serum-starved overnight followed by
treatment with vehicle or 11a-1 for 3 h, and then either left
unstimulated or stimulated with 5 ng/mL EGF (Sigma) for 60 min.
Lysates were then resolved by SDS-PAGE and the protein
phosphorylation levels were detected by immunoblot analysis.
Eﬀect of SHP2 Inhibitor 11a-1 on Breast Cancer Cells.
Approximately 300000 SKBR3 cells were seeded into 150 μL of
growth factor reduced Matrigel (Corning) in 35 mm dishes. To three
dishes for each condition, 2 mL of media containing either 10 μL of
vehicle (DMSO) or 11a-1 at the indicated concentration was then
added. Every 24 h, the cells were imaged with a NIKON SMZ1500
stereo microscope. The cross sectional area of individual colonies from
each image were measured using Adobe Photoshop software. After 4
days, the cells were recovered from the Matrigel and lysed in PLC
buﬀer containing protease inhibitor cocktail. Lysates were then
resolved by SDS-PAGE, and relative levels of the indicated proteins
were detected by immunoblot analysis.
Eﬀect of SHP2 Inhibitor II-B08 and 11a-1 on D32 Myeloid
Cells and Primary Hematopoietic Stem and Progenitor Cells.
The WT KIT and KITD814V were inserted into the bicistronic
retroviral vector, MIEG3, upstream of the internal ribosome entry site
(IRES) and the enhanced green ﬂuorescent protein (EGFP) gene as
previously described.50 Retroviral supernatants for transduction of 32D
myeloid cells and primary hematopoietic stem and progenitor cells
were generated using Phoenix ecotropic packaging cell line transfected
with retroviral vector plasmids using a calcium phosphate transfection
kit (Invitrogen, Carlsbad, CA). Supernatants were collected 48 h after
transfection and ﬁltered through 0.45 μm membranes. 32D myeloid
cells were infected twice at 24 h intervals with 2 mL of high-titer virus
supernatant in the presence of 10 ng/mL IL-3 and 8 μg/mL
Polybrene. Forty-eight hours after infection, 32D cells expressing WT
KIT or KITD814V receptors were sorted to homogeneity based on
EGFP expression and utilized to perform all the experiments.
To express WT KIT and KITD814V receptors in bone marrow
cells, low-density bone marrow cells were collected from WT mice,
and prestimulated in IMDM supplemented with 20% FBS, 2%
penicillin/streptomycin, and cytokines (100 ng/mL SCF, 100 ng/mL
TPO, 50 ng/mL FLT3-L, and 4 ng/mL IL-6) for 48 h prior to
retroviral infection on ﬁbronectin fragments (Retronectin) in
nontissue culture plates. On the third day, cells were infected with 2
mL of high-titer retroviral supernatants for WT KIT or KITD814V
prepared as described above. A second shot of viral infection was given
20 4 h later. Forty-eight hours after the second infection, cells
expressing EGFP were sorted and utilized to perform all experiments.
Proliferation was assessed by conducting a thymidine incorporation
assay as previously described (Mali et al., 201250). Cells were washed
and starved in IMDM containing 0.2% BSA without serum or any
growth factors for 6−8 h. Cells (5 × 104) were plated in replicates of
three in a 96-well plate in 200 μL of complete medium (IMDM, 10%
FBS, 2% penicillin−streptomycin) either in the presence or absence of
indicated growth factors with or without SHP2 inhibitors. Cells were
cultured for 48 h and subsequently pulsed with 1.0 μCi (0.037 MBq)
[3H] thymidine (PerkinElmer, Shelton, CT) for 6 h. Cells were
harvested using an automated 96-well cell harvester (Brandel,
Gaithersburg, MD), and thymidine incorporation was determined as
counts per minute (CPM).
Immunoblot Analysis. Cells were lysed in lysis buﬀer (1.0%
Nonidet P-40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM
EDTA, 2 mM NaVO3, 10 mM NaF) plus a protease inhibitor mixture
(Roche) and centrifuged at 10000 rpm for 5 min at 4 °C. Supernatants
were collected and protein concentration was determined using the
BCA protein assay (Thermo Fisher Scientiﬁc, Rockford, IL). Equal
amount of protein extracts were mixed with gel loading buﬀer and
separated on SDS-polyacrylamide gels. After electrophoresis, the
proteins were transferred onto nitrocellulose membranes and
nonspeciﬁc binding was blocked with 5% nonfat dry milk in Tris-
buﬀered saline containing 0.1% Tween-20 (TBS-T). Membranes were
then probed with various antibodies overnight at 4 °C on a rocker.
After incubation, membranes were washed with TBS-T and incubated
with appropriate horseradish peroxidase (HRP)-conjugated secondary
antibodies for 1 h at room temperature. Finally, the proteins on the
membranes were detected using SuperSignal West Dura Luminol/
Enhancer solution (Thermo Fisher Scientiﬁc, Rockford, IL) and
membranes were analyzed using Bio-Rad ChemiDoc XRS Imaging
System.
RNA Interference Studies. Small interfering RNA (siRNA)
speciﬁc for SHP2 (5′-PCACGCAUGACGCCAUAUUCTT-3′) and
scrambled SHP2 siRNA (5′-PGCACGACCGCCUUAUAACUTT-3′)
were synthesized by Dharmacon Research. siRNAs were transfected
into H1975 cells by using Lipofectamine 2000 reagent (Invitrogen Life
Technologies) for 6 h and then recovered in RPMI1640 plus 10%
FBS.
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